PFE · Earnings event · Q2 2026 · archived
Pfizer (PFE) Q2 2026 earnings — TrendMatrix coverage
Reported · EPS $0.77 vs estimate $0.68 (+12.9%) — classified BEAT.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Event detail · Q2 2026
EPS beat/miss and revenue
| Metric | Estimate | Actual | Surprise |
|---|---|---|---|
| EPS (diluted) | $0.68 | $0.77 | +12.9% |
| Revenue (2026-06-28) | — | $15.03B | — |
Revenue source: xbrl.
Verdict reaction
How the verdict moved around this report
Before this report, TrendMatrix rated PFE Hold at 5.6/10. After the Q2 2026 report, the verdict moved to Buy (Wait) at 5.5/10.
Healthcare context
PFE at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Drug Manufacturers - General
- Market cap
- $152.69B
- P/E (fwd)
- 9.3
- P/E (ttm)
- 35.3
- 52-week range
- $23.58–$28.75
- Off 52-week high
- 6.9%
- RSI (14)
- 75
- Volume vs avg
- 0.59×
- Engine score
- 5.2/10
Live context at TrendMatrix’s latest engine read — updates after the report date; not frozen to it.